{
    "type": "ETP",
    "ucits": false,
    "replication_method": "synthetic",
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "complex_factors": [
        "3x daily leverage",
        "Synthetic replication via swaps",
        "Counterparty risk (Natixis as swap provider)",
        "Collateralized structure with BNY Mellon",
        "High volatility compounding effects",
        "Intended for sophisticated investors only"
    ],
    "classification": "complex",
    "supporting_data": "The GraniteShares 3x Long AstraZeneca Daily ETP is classified as complex under MiFID II due to several key factors: 1) It uses synthetic replication through a swap agreement with Natixis, creating counterparty risk; 2) The 3x daily leverage mechanism introduces significant volatility and compounding effects that make performance unpredictable over longer periods; 3) The product is explicitly stated to be for sophisticated investors who understand leverage and daily rebalancing; 4) The risk profile (7/7) and disclosures about potential total loss of investment confirm the complexity. While the collateralization mitigates some counterparty risk, the leveraged nature and daily reset mechanism make this product unsuitable for retail investors without specialized knowledge. The PRIIPs KID's 'comprehension warning' and the fact sheet's emphasis on daily monitoring requirements further support this classification.",
    "confidence": 95
}